Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Recruiting 5Active not recruiting 3Terminated 1Completed 1

Sponsor Class

NIH 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 257Neoplasms 225Carcinoma, Non-Small-Cell Lung 206Colorectal Neoplasms 148Prostatic Neoplasms 142Lung Neoplasms 116Neoplasm Metastasis 106Ovarian Neoplasms 103Multiple Myeloma 98Pancreatic Neoplasms 89Leukemia, Myeloid, Acute 79Squamous Cell Carcinoma of Head and Neck 75Endometrial Neoplasms 65Melanoma 64Stomach Neoplasms 60Recurrence 59Glioblastoma 57Brain Neoplasms 56Urinary Bladder Neoplasms 51Carcinoma, Hepatocellular 51Triple Negative Breast Neoplasms 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Lymphoma 48Head and Neck Neoplasms 47Carcinoma, Renal Cell 46Hematologic Neoplasms 44Esophageal Neoplasms 43Colonic Neoplasms 43Uterine Cervical Neoplasms 42Glioma 42

Interventions

Tamoxifen 4Specimen Handling 3exemestane 1elacestrant 1Testosterone 1Omacor 1Letrozole 1FAPI-46 1Biopsy 1Anastrozole 14-hydroxy-N-desmethyltamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Intraductal, Noninfiltrating × 30 days × Clear all
NCT06540872 2026-06-03

MI-CISDIR

Universität Münster

Phase 2 Recruiting
30 enrolled
Breast

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06075953 2026-05-22

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
400 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT06195306 2026-05-20

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

National Cancer Institute (NCI)

Phase 2 Recruiting
66 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT05941520 2026-05-13

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
80 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06184750 2026-05-13

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
200 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡